Gene therapy of haematopoietic stem cells aims at a life-long therapeutically effective correction of these cells in humans with particular genetic disorders. This therapeutic approach has proved to be effective in clinical trials while the risk of leukaemia development as a side-effect of the therapy must be kept as low as possible. In an international research network, researchers of the Paul-Ehrlich-Institut have developed a method using "jumping genes" (transposons) to transfer genes efficiently and to anchor them in the genome of the modified cells. Molecular Therapy reports on the results.
In gene therapy of certain congenital disorders, the therapeutic gene is transferred into the target cells using particular transport vehicles, also known as vectors. Gene transfer into haematopoietic (blood forming) stem cells has been successfully tested in clinical trials for the treatment of various genetic disorders caused by a defect in one particular gene (monogenetic).
Stable gene transfer and expression of a Venus fluorescence marker gene mediated by Sleeping Beauty transposons in hematopoietic progenitor cells.
Examples include certain immune defects such as the group of Severe Combined Immune Deficiency disorders (SCID). In some studies, however, isolated cases of oncogenic mutations triggered by gene vector integration led to cancer (leukaemia) as an undesired side-effect of the therapy. Major efforts have ever since been undertaken to develop safer vector systems.
The research team of Dr Zoltán Ivics, head of Division Medical Biotechnology of the Paul-Ehrlich-Institut uses Sleeping Beauty for therapeutic gene transfer into human cells. The Sleeping Beauty (SB) transposon system is a non-viral vector, which is low-cost to manufacture, relatively simple to use. Up to now, its clinical use for hematopoietic stem cell therapy has been hampered by technical challenges.
In an international collaboration with other researchers from Germany, Spain and France, Ivics and his team have shown that gene constructs can be incorporated 20-times more efficiently into the genomes of hematopoietic stem cells if minicircle DNA is used to carry the SB transposon. Minicircle DNA is very small because sequences used for the manufacturing process of plasmids have been removed.
In addition, the efficacy and safety of the stable gene transfer ex vivo (outside the body) into the haematopoietic stem cells could be significantly increased by providing the transposase enzyme in the form of a synthetic messenger DNA (mRNA). This enzyme is required for the gene transfer.
"We have methodologically further developed the Sleeping Beauty transposon system in such a way that clinical use of this method is now possible," said Dr Ivics, as he described the potential use of these research results.
Background: Transposon "Sleeping Beauty" and jumping genes
A transposon – jumping gene – is a section of DNA which can change its position in the genome (transposition). The ability to integrate itself into the genome can be used for the gene transfer. Sleeping Beauty is an artificial transposon derived from transposons occurring in fish as early as ten million years ago. The name was given to it based on Grimm's fairy tale "Sleeping Beauty".
Holstein M, Mesa-Nuñez C, Miskey C, Almarza E, Poletti V, Schmeer M, Grueso E, Ordóñez Flores JC, Kobelt D, Walther W, Aneja MK, Geiger J, Bonig HB, Izsvák Z, Schleef M, Rudolph C, Mavilio F, Bueren JA, Guenechea G, Ivics Z (2018):
Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors.
Mol Ther Jan 17 [Epub ahead of print].
The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects.
Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute.
The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).
https://www.sciencedirect.com/science/article/pii/S1525001618300194?via%3Dihub - Open Access full text article
https://www.pei.de/EN/information/journalists-press/press-releases/2018/04-sleep... - Link to this press release on the Website of the Paul-Ehrlich-Institut
Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft
Carnegie Mellon researchers probe hydrogen bonds using new technique
10.12.2018 | Carnegie Mellon University
A new molecular player involved in T cell activation
07.12.2018 | Tokyo Institute of Technology
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals
Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.
Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.
Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...
Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.
The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.
10.12.2018 | Event News
06.12.2018 | Event News
03.12.2018 | Event News
10.12.2018 | Physics and Astronomy
10.12.2018 | Life Sciences
10.12.2018 | Information Technology